MHRA reports mouse-study results for a potential needle-free Strep A vaccine
The UK agency’s October 27 account describes preclinical research on nasal or under-the-tongue vaccine delivery; it is not a licensed vaccine or human efficacy result.
What the record says
The UK Medicines and Healthcare products Regulatory Agency reported on October 27 research with the GSK Vaccines Institute for Global Health into a potential group A streptococcus vaccine. The agency says the work used a mouse model and Generalised Modules for Membrane Antigens technology to carry a Strep A carbohydrate and help stimulate immune responses. Its account describes delivery through the nose or under the tongue and immune responses at mucosal surfaces and throughout the body. MHRA says the findings support further development and that there is currently no licensed Strep A vaccine.
Source details and supporting locations.
Practical next step
Read the agency’s account for the research approach and its preclinical limits.
Limits and what is not established
These are attributed mouse-study findings, not evidence that a needle-free vaccine is approved, available or proven effective in humans. The underlying journal paper was not independently assessed for this report.
Sources checked October 27, 2026. Later notices may change instructions or arrangements.
Original sources
UK Medicines and Healthcare products Regulatory Agency: original information